Early subcutaneous administration of etanercept (enbrel) prevents from hyperoxia-induced lung injury

Experimental Lung Research

Volumn 35, Issue 9, 2009, Pages 770-780

  Guthmann, Florian ^a   Wissel, Heide ^a   Rüstow, Bernd ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Hyperoxia; Lung; Lung injury; Rat; TNF

Indexed keywords

CASPASE 3; ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY LEAK SYNDROME; CELL COUNT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GRANULOCYTE; HYPEROXIA; LUNG ALVEOLUS; LUNG ALVEOLUS CELL TYPE 2; LUNG INJURY; LUNG LAVAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPILLARY PERMEABILITY; CASPASE 3; GRANULOCYTES; HYPEROXIA; IMMUNOGLOBULIN G; LUNG INJURY; PULMONARY ALVEOLI; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70450210261     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902140902887430     Document Type: Article

References (25)

1. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL, Zhang X, Matthay MA,Ware LB, Homer RJ, Lee PJ, Geick A, de Fougerolles AR, Elias JA: Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med. 2006;12:1286-1293.
2. Murray LA, Knight DA, McAlonan L, Argentieri R, Joshi A, Shaheen F, Cunningham M, Alexopolou L, Flavell RA, Sarisky RT, Hogaboam CM: Deleterious role of TLR3 during hyperoxia-induced acute lung injury. Am J Respir Crit Care Med. 2008;178:1227-1237.
3. Crapo JD: Morphologic changes in pulmonary oxygen toxicity. Annu Rev Physiol. 1986;48:721-731.
4. Perkowski S, Sun J, Singhal S, Santiago J, Leikauf GD, Albelda SM: Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol. 2003;28:682-696.
5. Freeman BA, Mason RJ, Williams MC, Crapo JD: Antioxidant enzyme activity in alveolar type II cells after exposure of rats to hyperoxia. Exp Lung Res. 1986;10:203-222.
6. Stephens KE, Ishizaka A, Larrick JW, Raffin TA: Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. AmRev Respir Dis. 1988;137:1364-1370.
7. Wherry JC, Pennington JE, Wenzel RP: Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med. 1993;21:S436-S440.
8. Batenburg JJ, Haagsman HP: The lipids of pulmonary surfactant: dynamics and interactions with proteins. Prog Lipid Res. 1998;37:235-276.
9. Adamson IY, Bowden DH: The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposure to oxygen. Lab Invest. 1974;30:35-42.
10. Sabat R, Kolleck I, Witt W, Volk H, Sinha P, Rüstow B: Immunological dysregulation of lung cells in response to vitamin E deficiency. Free Radic Biol Med. 2001;30:1145-1153.
11. Crapo JD, Barry BE, Foscue HA, Shelburne J: Structural and biochemical changes in rat lungs occurring during exposures to lethal and adaptive doses of oxygen.AmRev RespirDis. 1980;122:123-143.
12. May M, Strobel P, Preisshofen T, Seidenspinner S, Marx A, Speer CP: Apoptosis and proliferation in lungs of ventilated and oxygen-treated preterm infants. Eur Respir J. 2004;23:113-121.
13. Janssen YM, Matalon S, Mossman BT: Differential induction of c-fos, c-jun, and apoptosis in lung epithelial cells exposed to ROS or RNS. Am J Physiol. 1997;273:L789-L796.
14. Gavino R, Johnson L, Bhandari V: Release of cytokines and apoptosis in fetal rat Type II pneumocytes exposed to hyperoxia and nitric oxide: modulatory effects of dexamethasone and pentoxifylline. Cytokine. 2002;20:247-255.
15. Lukkarinen HP, Laine J, Kaapa PO: Lung epithelial cells undergo apoptosis in neonatal respiratory distress syndrome. Pediatr Res. 2003;53:254-259.
16. O'Reilly MA, Staversky RJ, Stripp BR, Finkelstein JN: Exposure to hyperoxia induces p53 expression in mouse lung epithelium. Am J Respir Cell Mol Biol. 1998;18:43-50.
17. Guthmann F, Wissel H, Schachtrup C, Tölle A, Rüdiger M, Spener F, Rüstow B: Inhibition of TNFalpha in vivo prevents hyperoxia-mediated activation of caspase 3 in type II cells. Respir Res. 2005;6(1);10.
18. Sinha P, Kolleck I, Volk HD, Schlame M, Rüstow B: Vitamin E deficiency sensitizes alveolar type II cells for apoptosis. Biochim Biophys Acta. 2002;1583:91-98. (Pubitemid 34634099)
19. Kolleck I, Wissel H, Guthmann F, Schlame M, Sinha P, Rüstow B: HDL-holoparticle uptake by alveolar type II cells: effect of vitamin E status. Am J Respir Cell Mol Biol. 2002;27:57-63. (Pubitemid 34657391)
20. Dobbs LG, Gonzalez R, Williams MC: An improved method for isolating type II cells in high yield and purity. Am Rev Respir Dis. 1986;134:141-145.
21. Mazzon E, Cuzzocrea S: Role of TNF-alpha in lung tight junction alteration in mousemodel of acute lung inflammation. Respir Res. 2007;8(1);75.
22. Wilson MR, Choudhury S, Takata M: Pulmonary inflammation induced by high-stretch ventilation is mediated by tumor necrosis factor signaling in mice. Am J Physiol Lung Cell Mol Physiol. 2005;288:L599-L607.
23. Yu ML, Limper AH: Pneumocystis carinii induces ICAM-1 expression in lung epithelial cells through a TNF-alpha-mediated mechanism. Am J Physiol. 1997;273:L1103-L1111.
24. Renzetti LM,Gater PR: Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways. Inflamm Res. 1997;46(Suppl 2):S143-S144.
25. Li L, Das AM, Torphy TJ, Griswold DE: What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases. Pulm Pharmacol Ther. 2002;15:409-416.